ZYME Summary

  1. NYSE
  2. >
  3. ZYME
TickerZYME
DescriptionZYMEWORKS INC
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
ExchangeNYSE
TypeStock
SectorHealthcare
Employees354
Next Earnings DateNovember 2nd, 2022
IV94.246795%
IV Percentile44th
IV Rank20.84%
IV Skew-2.542979
IV Skew Percentile23rd
IV Skew SentimentBullish
Option Volume248
Volume268,010
Price$6.5291
Previous Close$7.00
52-Week High$37.19
52-Week Low$4.56
50-Day Moving Avg.$6.01
200-Day Moving Avg.$6.51
10-Day Avg. Volume1,256,767
20-Day Avg. Volume886,347
30-Day Avg. Volume872,017
3-Month Avg. Volume1,194,539
EPS-$4.93
Outstanding Shares57,892,785
Market Capitalization$374,935,100
CurrencyUSD
UpdatedAugust 9th, 2022